Inactivation of cell-free HIV-1 by designing potent peptides based on mutations in the CD4 binding site.

Abstract excerpt

Human immunodeficiency virus type 1 (HIV-1) is a major global health problem, with over 38 million people infected worldwide. Current anti-HIV-1 drugs are limited in their ability to prevent the virus from replicating inside host cells, making them less effective as preventive measures. In contrast, viral inhibitors that inactivate the virus before it can bind to a host cell have great potential as drugs. In this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Binding Sites
• Share to CD4 Antigens